Igf-1 des

Mechanism of action

It binds primarily to the IGF-1R receptor (tyrosine kinase), activating the PI3K–AKT–mTOR pathways (cell survival, protein synthesis, metabolism) and RAS–RAF–MEK–ERK (proliferation/differentiation). It may show cross-talk with the insulin receptor (IR) and with hybrid IGF-1R/IR receptors, with potential effects on glucose metabolism. The 1–3 deletion reduces affinity for IGFBP (particularly IGFBP-3), increasing the free fraction and mitogenic activity in some models, with greater emphasis on local effects rather than a stable endocrine profile.

Supported benefits

• Stimulation of cell proliferation and migration (mitogenic effects) in in vitro models (moderate)
• Support for tissue repair/regeneration processes in animal models (dependent on tissue type and injury context) (limited)
• Increase in protein synthesis and anabolic signaling (PI3K/AKT/mTOR) in experimental models (limited)
• Improvement in local growth parameters in specific preclinical models (e.g. muscle/bone/tendons under experimental conditions) (emerging)

Safety & side effects

• Hypoglycemia or changes in blood glucose (due to cross-talk with insulin signaling), with symptoms such as weakness, sweating, tremors, confusion.
• Edema/fluid retention and joint pain: effects reported with modulation of the IGF axis in general, plausible but not well quantified for IGF-1 DES.
• Headache, nausea, local reactions at the administration site (in parenteral contexts).
• Possible increase in unwanted cell proliferation: theoretical risk of promoting growth of pre-neoplastic or neoplastic lesions in predisposed individuals (mitogenic mechanism).
• Alterations in growth markers (e.g. bioactive IGF) with potential effects on sensitive tissues (breast, prostate, colon) depending on the biological context.

FAQ

What is the difference between IGF-1 and IGF-1 DES?

IGF-1 DES is a truncated form (the first 3 amino acids are missing) that tends to bind less to IGF-binding proteins, increasing the free fraction and often the mitogenic potency in experimental models. Native IGF-1 is more regulated by IGFBPs and has more controlled endocrine dynamics.

Is it a supplement?

No. It is a research peptide; it is not a nutraceutical, and there is insufficient evidence to consider it a safe or appropriate supplementation intervention.

Can it improve muscle mass or performance?

The hypotheses derive from biological mechanisms and preclinical studies. Solid clinical data demonstrating reliable benefits for hypertrophy, strength, or performance in humans are lacking, while the potential risks are significant.

What is the main risk?

Two critical areas: (1) changes in blood glucose (including hypoglycemia) due to interactions with insulin pathways; (2) potential promotion of unwanted cell proliferation, given the mitogenic activity on IGF-1R.

Why is the half-life considered short?

Reduced interaction with IGFBP may increase free activity but does not guarantee systemic stability; peptides are subject to rapid degradation and clearance, with half-lives often on the order of minutes in circulation.